ARVELLE THERAPEUTICS
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.
ARVELLE THERAPEUTICS
Industry:
Biotechnology
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.arvelletx.com
Total Employee:
1+
Status:
Active
Contact:
(888) 317-1041
Total Funding:
221.85 M USD
Technology used in webpage:
Euro Google Font API Font Awesome Nginx GStatic Google Static Content
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
CarbonWorks
CarbonWorks is specialising in the use of microalgae to capture and utilise carbon dioxide.
Colorifix
Colorifix is the first company to use a biological process to produce, deposit and fix pigments onto textiles.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is a bioelectronics company using graphene to build the least invasive and most intelligent neural platform
Lightcast Discovery
Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.
Micropep Technologies
Micropep Technologies is a biotech company that focused on biological alternatives to agrochemicals.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Founder
Investors List
KB Investment
KB Investment investment in Series A - Arvelle Therapeutics
H.I.G. BioHealth Partners
H.I.G. BioHealth Partners investment in Series A - Arvelle Therapeutics
BPV Capital Management
BPV Capital Management investment in Series A - Arvelle Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Series A - Arvelle Therapeutics
Andera Partners
Andera Partners investment in Series A - Arvelle Therapeutics
F-Prime Capital
F-Prime Capital investment in Series A - Arvelle Therapeutics
Novaquest Capital Management
Novaquest Capital Management investment in Series A - Arvelle Therapeutics
BPV Capital Management
BPV Capital Management investment in Series A - Arvelle Therapeutics
Novaquest Capital Management
Novaquest Capital Management investment in Series A - Arvelle Therapeutics
H.I.G. BioHealth Partners
H.I.G. BioHealth Partners investment in Series A - Arvelle Therapeutics
Official Site Inspections
http://www.arvelletx.com
- Host name: 104.21.31.209
- IP address: 104.21.31.209
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arvelle Therapeutics"
Arvelle Therapeutics - Crunchbase Company Profile & Funding
Organization. Arvelle Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Arvelle Therapeutics is a …See details»
Angelini Pharma today finalized the acquisition agreement of …
Feb 2, 2021 Juan Vergez - Head of Marketing and Corporate Communications - Email: Juan.Vergez@arvelletx.com. SK Biopharmaceuticals. Hyongki Park - Head of …See details»
Angelini Pharma acquires Arvelle Therapeutics
Jan 4, 2021 Juan Vergez - Head of Marketing and Corporate Communications - Juan.Vergez@arvelletx.com Consilium Strategic: Communications (international strategic …See details»
Arvelle Therapeutics - EQT Group
Nov 26, 2024 Latest news. 02 December 2024 EQT and GIC to acquire majority stake in Calisen, a leading independent smart metering company in the UK; 29 November 2024See details»
Angelini Pharma acquires Arvelle Therapeutics to create a leading ...
Jan 4, 2021 They have worked in close collaboration with the European regulators to advance the marketing authorization application (MAA), and they have successfully prepared for launch …See details»
Angelini Pharma acquires Arvelle Therapeutics
Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering …See details»
Arvelle Therapeutics Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Arvelle Therapeutics Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Angelini Pharma acquires Arvelle Therapeutics to create a leading ...
ROME, Jan. 14, 2021 /PRNewswire/ -- Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and Arvelle Therapeutics, a …See details»
Arvelle Therapeutics - Overview, News & Similar companies
Jan 5, 2021 www.arvelletx.com. Revenue $19.7 Million. Industry Pharmaceuticals Healthcare . Recent News & Media. Angelini Pharma acquires Arvelle Therapeutics to create a le... Jan 14, …See details»
Arvelle Therapeutics - Company Profile - Tracxn
Aug 17, 2021 Arvelle Therapeutics - Developer of small molecules for the treatment of partial-onset seizures. Acquired by Angelini Pharma. Raised a total funding of $223M over 2 rounds …See details»
Arvelle Therapeutics - Craft
Arvelle Therapeutics is a biopharmaceutical company. The company licenced the anti-epileptic candidate cenobamate (YKP3089). Cenobamate is used for the treatment of adults with focal …See details»
Arvelle’s Competitors, Revenue, Number of Employees, Funding
Arvelle’s Profile, Revenue and Employees. Arvelle is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of central nervous system disorders. …See details»
Arvelle Therapeutics - PitchBook
Arvelle Therapeutics General Information Description. Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders.See details»
Arvelle Therapeutics Company Profile -Sales, Contacts, …
Arvelle Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 5 years.See details»
About Us | Arvelle Therapeutics
Info@arvelletx.co.uk. Regus Oxford Street (Oxford Circus) 33 Cavendish Square, London, Greater London W1G 0PW United Kingdom. UK11420P | April 2022 +44 (20) 81247407. …See details»
Arvelle Therapeutics GmbH (aquired by Angelini Pharma)
Arvelle Therapeutics GmbH (aquired by Angelini Pharma): Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients …See details»
Arvelle Therapeutics | H.I.G. BioHealth Partners
Arvelle Therapeutics is a biopharmaceutical company bringing innovative solutions to patients suffering from CNS disorders. Arvelle Therapeutics is a biopharmaceutical company with the …See details»
Arvelle Therapeutics (Switzerland) Funding: $221.8M
Nov 23, 2024 Arvelle carries forward the European rights to cenobamate, an anti-epileptic drug for partial-onset...See details»
NovaQuest Capital Enters Into Financing Agreement With Arvelle ...
BASEL, Switzerland–(BUSINESS WIRE)–SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for …See details»
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the …
Jan 29, 2021 Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with …See details»